Genetic discovery will help clinicians identify aggressive versus benign bone tumors

(Wellcome Trust Sanger Institute) The first genetic marker for the bone tumor, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results, published in Nature Communications, will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive...